Statistiche di base
| LEI | 5493004WF12U6NOV8U20 |
| CIK | 1583771 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Hepion Pharmaceuticals, Inc.
SEC Filings (Chronological Order)
Questa pagina fornisce un elenco completo e cronologico dei depositi SEC, esclusi i documenti di proprietà che forniamo altrove.
| August 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2025 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36856 HEPION PHARMACEUTICALS |
|
| June 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 25, 2025 Hepion Pharmaceuticals, Inc. |
|
| June 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 12, 2025 Hepion Pharmaceuticals, Inc. |
|
| June 9, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 3, 2025 Hepion Pharmaceuticals, Inc. |
|
| May 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 26, 2025 Hepion Pharmaceuticals, Inc. |
|
| May 19, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2025 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36856 HEPION PHARMACEUTICAL |
|
| May 19, 2025 |
Exhibit 10.1 [*] Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed. INTELLECTUAL PROPERTY LICENSE AGREEMENT This Intellectual Property License Agreement (“Agreement”) is entered into this 9th day of May 2025 (“Effective Date”), by and between New Day Diagnostics LLC, a Delaware l |
|
| May 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 Commission File Number: 001-36856 NOTIFICATION OF LATE FILING ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR For Period Ended: March 31, 2025 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 10-Q ☐ Transition Report on Form 20-F ☐ Transition Report on Form N-SAR ☐ |
|
| May 12, 2025 |
Hepion Pharmaceuticals Announces Receipt of Delisting Notification from Nasdaq Exhibit 99.1 Hepion Pharmaceuticals Announces Receipt of Delisting Notification from Nasdaq MORRISTOWN, N.J., May 12, 2025 — Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company that had been developing a treatment for non-alcoholic steatohepatitis (“NASH”), hepatocellular carcinoma (“HCC”), and other chronic liver diseases which has transitioned to a developer an |
|
| May 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2025 Hepion Pharmaceuticals, Inc. |
|
| May 6, 2025 |
Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 30, 2025 Hepion Pharmaceuticals, Inc. |
|
| April 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Information Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| April 23, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Information Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| April 17, 2025 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 15, 2025 Hepion Pharmaceuticals, Inc. |
|
| April 16, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Information Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| April 8, 2025 |
Exhibit 19.1 HEPION PHARMACEUTICALS, INC. INSIDER TRADING POLICY and Guidelines with Respect to Certain Transactions in Company Securities This Policy provides guidelines to employees, officers and directors of Hepion Pharmaceuticals, Inc. (the “Company”) with respect to transactions in the Company’s securities. Applicability of Policy This Policy applies to all transactions in the Company’s secur |
|
| April 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the year ended December 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 001-36856 HEPION PHARMACEUTICALS, INC. (E |
|
| April 8, 2025 |
Exhibit 21.1 LIST OF SUBSIDIARIES Name State or Other Jurisdiction of Incorporation ContraVir Research, Inc. Delaware Hepion Research Corp. Canada |
|
| April 4, 2025 |
Hepion Pharmaceutical Consolidated Balance Sheets January 31, 2025 Exhibit 99.1 Hepion Pharmaceutical Consolidated Balance Sheets January 31, 2025 PBC January 31, 2025 (Unaudited) ASSETS Current Assets Cash 5,219,944.00 Prepaid expenses 1,142,329.00 Related party receivable - Total Current Assets $ 6,362,273.00 Property and equipment, net - Right-of-use assets - Other assets - In Process R&D - TOTAL ASSETS $ 6,362,273.00 LIABILITIES AND STOCKHOLDERS’ EQUITY Curre |
|
| April 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 4, 2025 Hepion Pharmaceuticals, Inc. |
|
| April 1, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 Commission File Number: 001-36856 NOTIFICATION OF LATE FILING ☒ Form 10-K ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR For Period Ended: December 31, 2024 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 10-Q ☐ Transition Report on Form 20-F ☐ Transition Report on Form N-SAR |
|
| March 20, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 18, 2025 Hepion Pharmaceuticals, Inc. |
|
| March 19, 2025 |
Certificate Amendment of the Certificate of Incorporation of Hepion Pharmaceuticals, Inc. Exhibit 3.1 |
|
| March 19, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 17, 2025 Hepion Pharmaceuticals, Inc. |
|
| March 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2025 Hepion Pharmaceuticals, Inc. |
|
| March 4, 2025 |
Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 4, 2025 Hepion Pharmaceuticals, Inc. |
|
| March 4, 2025 |
Exhibit 99.1 HEPION PHARMACEUTICALS, INC. AND SUBSIDIARIES Unaudited Consolidated Balance Sheet as of January 31, 2025 January 31, 2025 Assets Current assets: Cash $ 5,362,641 Prepaid expenses 1,142,329 Total current assets 6,504,970 Total assets $ 6,504,970 Liabilities and Stockholders’ Equity Current liabilities: Accounts payable $ 220,202 Notes payable, current — Total current liabilities 220,2 |
|
| February 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Information Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| January 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Information Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| January 24, 2025 |
EX-99.1 2 ex991to13g10022hepa012425.htm Exhibit 99.1 Joint Filing Agreement The undersigned hereby agree that the Statement on Schedule 13G dated January 24, 2025 with respect to the shares of Common Stock of Hepion Pharmaceuticals, Inc. and any further amendments thereto executed by each and any of the undersigned shall be filed on behalf of each of the undersigned pursuant to and in accordance w |
|
| January 23, 2025 |
Filed Pursuant to Rule 424(b)(4) Registration Number 333-284052 PROSPECTUS Hepion Pharmaceuticals, Inc. |
|
| January 21, 2025 |
As filed with the U.S. Securities and Exchange Commission on January 21, 2025. As filed with the U.S. Securities and Exchange Commission on January 21, 2025. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Hepion Pharmaceuticals, Inc. (Exact name of Registrant as specified in its charter) Not Applicable (Translation of Registrant’s Name into English) Delaware 2834 4 |
|
| January 21, 2025 |
Exhibit 107 Calculation of Filing Fee Tables FORM S-1 (Form Type) HEPION PHARMACEUTICALS, INC. |
|
| January 17, 2025 |
CORRESP 1 filename1.htm Hepion Pharmaceuticals, Inc. c/o Clementi Associates 919 Conestoga Road Building 3, Suite 115 Rosemont, PA 19010 January 17, 2025 VIA EDGAR United States Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attention: Jason Drory Re: Hepion Pharmaceuticals, Inc. Form S-1 Registration Statement, as amended Filed December 26, 2024 File No. 333-284052 L |
|
| January 17, 2025 |
Laidlaw & Company (UK) Ltd. 521 5th Ave, New York, NY 10175 January 17, 2025 Laidlaw & Company (UK) Ltd. 521 5th Ave, New York, NY 10175 January 17, 2025 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Hepion Pharmaceuticals, Inc. Registration Statement on Form S-1, as amended File No: 333-284052 Ladies and Gentlemen: Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended |
|
| January 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 14, 2025 Hepion Pharmaceuticals, Inc. |
|
| January 15, 2025 |
Hepion Pharmaceuticals, Inc. c/o Clementi Associates 919 Conestoga Road Building 3, Suite 115 Rosemont, PA 19010 January 15, 2025 VIA EDGAR United States Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attention: Jason Drory Re: Hepion Pharmaceuticals, Inc. Form S-1 Registration Statement, as amended Filed December 26, 2024 File No. 333-284052 Ladies and Gentlemen: Ref |
|
| January 15, 2025 |
Laidlaw & Company (UK) Ltd. 521 5th Ave, New York, NY 10175 Laidlaw & Company (UK) Ltd. 521 5th Ave, New York, NY 10175 January 15, 2025 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Hepion Pharmaceuticals, Inc. (the “Company”) Registration Statement on Form S-1, as amended File No: 333-284052 (the “Registration Statement”) Ladies and Gentlemen: Reference is made to our lette |
|
| January 14, 2025 |
Laidlaw & Company (UK) Ltd. 521 5th Ave, New York, NY 10175 Laidlaw & Company (UK) Ltd. 521 5th Ave, New York, NY 10175 January 14, 2025 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Hepion Pharmaceuticals, Inc. Registration Statement on Form S-1, as amended File No: 333-284052 Ladies and Gentlemen: Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended |
|
| January 14, 2025 |
As filed with the Securities and Exchange Commission on January 14, 2025 As filed with the Securities and Exchange Commission on January 14, 2025 Registration Statement No. |
|
| January 14, 2025 |
Hepion Pharmaceuticals, Inc. c/o Clementi Associates 919 Conestoga Road Building 3, Suite 115 Rosemont, PA 19010 January 14, 2025 VIA EDGAR United States Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attention: Jason Drory Re: Hepion Pharmaceuticals, Inc. Form S-1 Registration Statement, as amended Filed December 26, 2024 File No. 333-284052 Ladies and Gentlemen: Pur |
|
| January 14, 2025 |
Form of Placement Agency Agreement** Exhibit 1.1 PLACEMENT AGENCY AGREEMENT Laidlaw & Company (UK) Ltd. 521 5th Ave, New York, NY 10175 January [], 2025 Ladies and Gentlemen: This letter (this “Agreement”) constitutes the agreement between Hepion Pharmaceuticals, Inc., a Delaware corporation (the “Company”) and Laidlaw & Company (UK) Ltd. (“Laidlaw”) pursuant to which Laidlaw shall serve (the “Services”) as the placement agent (the “ |
|
| January 14, 2025 |
Exhibit 4.8 SERIES B COMMON STOCK PURCHASE WARRANT HEPION PHARMACEUTICALS, INC. Warrant Shares: [*] Issuance Date: January [], 2025 THIS SERIES B COMMON STOCK PURCHASE WARRANT (“Warrant”) certifies that, for value received, [] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the Sh |
|
| January 14, 2025 |
Form of Securities Purchase Agreement** Exhibit 10.7 SECURITIES PURCHASE AGREEMENT THIS SECURITIES PURCHASE AGREEMENT (this “Agreement”) is entered into and made effective as of January [], 2025, between Hepion Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, su |
|
| January 14, 2025 |
Exhibit 4.7 SERIES A COMMON STOCK PURCHASE WARRANT HEPION PHARMACEUTICALS, INC. Warrant Shares: [*] Issuance Date: January [], 2025 THIS SERIES A COMMON STOCK PURCHASE WARRANT (“Warrant”) certifies that, for value received, [] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the Sh |
|
| January 14, 2025 |
Exhibit 4.6 PRE-FUNDED COMMON STOCK PURCHASE WARRANT HEPION PHARMACEUTICALS, INC. Warrant Shares: [*] Issuance Date: January [], 2025 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, [] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth at any time on or after |
|
| January 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 2) (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the year ended December 31, 2023 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36856 HE |
|
| December 26, 2024 |
As filed with the Securities and Exchange Commission on December 26, 2024 As filed with the Securities and Exchange Commission on December 26, 2024 Registration Statement No. |
|
| December 26, 2024 |
Exhibit 107 Calculation of Filing Fee Tables FORM S-1 (Form Type) HEPION PHARMACEUTICALS, INC. |
|
| December 11, 2024 |
Hepion Pharmaceuticals, Inc. Announces Termination of Merger Agreement with Pharma Two B Ltd. Exhibit 99.1 Hepion Pharmaceuticals, Inc. Announces Termination of Merger Agreement with Pharma Two B Ltd. EDISON, N.J., December 11, 2024 —Hepion Pharmaceuticals, Inc. (Nasdaq: HEPA) (the “Company” or “Hepion”), a clinical stage biopharmaceutical company that had been developing a treatment for non-alcoholic steatohepatitis (“NASH”), hepatocellular carcinoma (“HCC”), and other chronic liver disea |
|
| December 11, 2024 |
Exhibit 10.1 TERMINATION AGREEMENT This TERMINATION AGREEMENT (this “Agreement”) is made as of December 10, 2024 by and between Pharma Two B Ltd. (the “Company”), Hepion Pharmaceuticals, Inc. (“Hepion”) and Pearl Merger Sub, Inc. (“Merger Sub”) (the Company, Hepion and Merger Sub collectively, the “Parties” and individual a “Party”). RECITALS Reference is made to the Agreement and Plan of Merger b |
|
| December 11, 2024 |
Termination of a Material Definitive Agreement, Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 10, 2024 Hepion Pharmaceuticals, Inc. |
|
| December 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| December 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| November 21, 2024 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 20, 2024 Hepion Pharmaceuticals, Inc. |
|
| November 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 20, 2024 Hepion Pharmaceuticals, Inc. |
|
| November 14, 2024 |
HEPA / Hepion Pharmaceuticals, Inc. / ARMISTICE CAPITAL, LLC Passive Investment SC 13G/A 1 armistice-hepa093024a1.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* HEPION PHARMACEUTICALS, INC. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 426897302 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statemen |
|
| November 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2024 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36856 HEPION PHARMACEUT |
|
| September 5, 2024 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 3, 2024 Hepion Pharmaceuticals, Inc. |
|
| September 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 3, 2024 Hepion Pharmaceuticals, Inc. |
|
| August 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2024 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36856 HEPION PHARMACEUTICALS |
|
| August 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2024 Hepion Pharmaceuticals, Inc. |
|
| August 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2024 Hepion Pharmaceuticals, Inc. |
|
| July 22, 2024 |
Form of Securities Purchase Agreement Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of July [●], 2024, between Hepion Pharmaceuticals, Inc., a Delaware corporation (the “Company”) and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”). WHEREAS, subject to the terms and condi |
|
| July 22, 2024 |
Exhibit 4.1 [FORM OF SENIOR UNSECURED NONCONVERTIBLE NOTE] THIS SECURITY HAS NOT BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT |
|
| July 22, 2024 |
Form of Registration Rights Agreement Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of [●], 2024, by and among Pharma Two B Ltd, a corporation incorporated in Israel, with headquarters located at 4 Oppenheimer Street, Rehovot, Israel 7670104 (the “Company”), Hepion Pharmaceuticals, Inc., a Delaware corporation (“Hepion”) and the Buyers (as defined below). WHEREAS: A. In connectio |
|
| July 22, 2024 |
Exhibit 2.1 EXECUTION AGREEMENT AND PLAN OF MERGER by and among PHARMA TWO B LTD. PEARL MERGER SUB, INC. and HEPION PHARMACEUTICALS, INC. dated as of JULY 19, 2024 TABLE OF CONTENTS Page Article I CERTAIN DEFINITIONS 2 Section 1.01 Definitions 2 Section 1.02 Construction 11 Article II PRE-CLOSING TRANSACTIONS; THE MERGER 12 Section 2.01 Pre-Closing Transactions 12 Section 2.02 The Merger 12 Sectio |
|
| July 22, 2024 |
Transaction Presentation dated July 22, 2024 Exhibit 99.1 |
|
| July 22, 2024 |
Exhibit 99.2 Pharma Two B Announces Plans to Go Public via Merger with Hepion Pharmaceuticals, Inc. and Concurrent $11.5 Million Private Placement ● Pharma Two B Ltd. (“Pharma Two B”) has entered into a merger agreement with Hepion Pharmaceuticals, Inc. (“Hepion”) (Nasdaq: HEPA) ● Immediately upon completion of the merger, current Pharma Two B equity-holders will own approximately 85% of the combi |
|
| July 22, 2024 |
Transaction Presentation dated July 22, 2024 Exhibit 99.1 |
|
| July 22, 2024 |
Exhibit 2.1 EXECUTION AGREEMENT AND PLAN OF MERGER by and among PHARMA TWO B LTD. PEARL MERGER SUB, INC. and HEPION PHARMACEUTICALS, INC. dated as of JULY 19, 2024 TABLE OF CONTENTS Page Article I CERTAIN DEFINITIONS 2 Section 1.01 Definitions 2 Section 1.02 Construction 11 Article II PRE-CLOSING TRANSACTIONS; THE MERGER 12 Section 2.01 Pre-Closing Transactions 12 Section 2.02 The Merger 12 Sectio |
|
| July 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 19, 2024 Hepion Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36856 46-2783806 (State or other jurisdiction of incorporation) (Commiss |
|
| July 22, 2024 |
Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of [●], 2024, by and among Pharma Two B Ltd, a corporation incorporated in Israel, with headquarters located at 4 Oppenheimer Street, Rehovot, Israel 7670104 (the “Company”), Hepion Pharmaceuticals, Inc., a Delaware corporation (“Hepion”) and the Buyers (as defined below). WHEREAS: A. In connectio |
|
| July 22, 2024 |
Exhibit 10.4 Lock-Up Agreement [●], 2024 Ladies and Gentlemen: The undersigned stockholder of Hepion or shareholder of the Company (as the case may be) (the “Shareholder”) understands that: (i) Hepion Pharmaceuticals, Inc., a Delaware corporation (“Hepion”), has entered into an Agreement and Plan of Merger, dated as of July [●], 2024 (the “Merger Agreement”), with Pharma Two B Ltd., an Israeli lim |
|
| July 22, 2024 |
Exhibit 10.4 Lock-Up Agreement [●], 2024 Ladies and Gentlemen: The undersigned stockholder of Hepion or shareholder of the Company (as the case may be) (the “Shareholder”) understands that: (i) Hepion Pharmaceuticals, Inc., a Delaware corporation (“Hepion”), has entered into an Agreement and Plan of Merger, dated as of July [●], 2024 (the “Merger Agreement”), with Pharma Two B Ltd., an Israeli lim |
|
| July 22, 2024 |
Exhibit 99.2 Pharma Two B Announces Plans to Go Public via Merger with Hepion Pharmaceuticals, Inc. and Concurrent $11.5 Million Private Placement ● Pharma Two B Ltd. (“Pharma Two B”) has entered into a merger agreement with Hepion Pharmaceuticals, Inc. (“Hepion”) (Nasdaq: HEPA) ● Immediately upon completion of the merger, current Pharma Two B equity-holders will own approximately 85% of the combi |
|
| July 22, 2024 |
Exhibit 10.3 FORM OF SUPPORT AGREEMENT This Support Agreement (this “Agreement”) is made as of [●], 2024 by and among (i) Hepion Pharmaceuticals, Inc., a Delaware corporation (“Hepion”), (ii) Pharma Two B Ltd., a company organized under the laws of the State of Israel (the “Company”), and (iii) the undersigned shareholder (“Holder”) of Hepion. Any capitalized term used but not defined in this Agre |
|
| July 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 19, 2024 Hepion Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36856 46-2783806 (State or other jurisdiction of incorporation) (Commiss |
|
| July 22, 2024 |
Form of Senior Unsecured Nonconvertible Note Exhibit 4.1 [FORM OF SENIOR UNSECURED NONCONVERTIBLE NOTE] THIS SECURITY HAS NOT BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT |
|
| July 22, 2024 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of July [●], 2024, between Hepion Pharmaceuticals, Inc., a Delaware corporation (the “Company”) and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”). WHEREAS, subject to the terms and condi |
|
| July 22, 2024 |
Exhibit 10.3 FORM OF SUPPORT AGREEMENT This Support Agreement (this “Agreement”) is made as of [●], 2024 by and among (i) Hepion Pharmaceuticals, Inc., a Delaware corporation (“Hepion”), (ii) Pharma Two B Ltd., a company organized under the laws of the State of Israel (the “Company”), and (iii) the undersigned shareholder (“Holder”) of Hepion. Any capitalized term used but not defined in this Agre |
|
| July 15, 2024 |
Hepion Pharmaceuticals, Inc. Up to 1,470,590 shares of Common Stock PROSPECTUS Filed Pursuant to Rule 424(b)(3) Registration No. 333-280752 Hepion Pharmaceuticals, Inc. Up to 1,470,590 shares of Common Stock Pursuant to this prospectus, the selling stockholder identified herein (the “Selling Stockholder”) is offering on a resale basis an aggregate of up to 1,470,590 shares of common stock of Hepion Pharmaceuticals, Inc. (the “Company,” “we,” “us” or our”), par val |
|
| July 12, 2024 |
Hepion Pharmaceuticals, Inc. 399 Thornall Street, First Floor Edison, NJ 08837 Hepion Pharmaceuticals, Inc. 399 Thornall Street, First Floor Edison, NJ 08837 July 12, 2024 VIA EDGAR United States Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attention: Jimmy McNamara Re: Hepion Pharmaceuticals, Inc. Form S-1 Registration Statement Filed July 11, 2024 File No. 333-280752 Ladies and Gentlemen: Pursuant to Rule 461 of the General Rules and Regulat |
|
| July 11, 2024 |
Exhibit 107 Calculation of Filing Fee Tables FORM S-1 (Form Type) HEPION PHARMACEUTICALS, INC. |
|
| July 11, 2024 |
As filed with the Securities and Exchange Commission on July 11, 2024 As filed with the Securities and Exchange Commission on July 11, 2024 Registration Statement No. |
|
| June 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the year ended December 31, 2023 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36856 HEPION PHARMACEUTICA |
|
| May 21, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2024 Or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36856 HEP |
|
| May 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 Commission File Number: 001-36856 NOTIFICATION OF LATE FILING ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR For Period Ended: March 31, 2024 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 10-Q ☐ Transition Report on Form 20-F ☐ Transition Report on Form N-SAR ☐ |
|
| April 16, 2024 |
Exhibit 97.1 Hepion Pharmaceuticals, Inc. CLAWBACK POLICY A.Purpose and Scope The Board of Directors (the “Board”) of the Company believes that it is in the best interests of the Company and its shareholders to create and maintain a culture that emphasizes integrity and accountability and that reinforces the Company’s pay-for-performance compensation philosophy. The Board has therefore adopted thi |
|
| April 16, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the year ended December 31, 2023 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 001-36856 HEPION PHARMA |
|
| April 16, 2024 |
Exhibit 21.1 LIST OF SUBSIDIARIES Name State or Other Jurisdiction of Incorporation ContraVir Research, Inc. Delaware Hepion Research Corp. Canada |
|
| April 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 Commission File Number: 001-36856 NOTIFICATION OF LATE FILING x Form 10-K ¨ Form 20-F ¨ Form 11-K ¨ Form 10-Q ¨ Form 10-D ¨ Form N-SAR ¨ Form N-CSR For Period Ended: December 31, 2023 ¨ Transition Report on Form 10-K ¨ Transition Report on Form 10-Q ¨ Transition Report on Form 20-F ¨ Transition Report on Form N-SAR |
|
| March 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 5, 2024 Hepion Pharmaceuticals, Inc. |
|
| February 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 20, 2024 Hepion Pharmaceuticals, Inc. |
|
| February 16, 2024 |
Exhibit 10.1 HEPION PHARMACEUTICALS, INC. 399 Thornall Street, First Floor Edison, NJ 08837 February 15, 2024 To the Holder of Series B Common Stock Purchase Warrants of Hepion Pharmaceuticals, Inc. Issued on October 3, 2023 Re: Warrant Inducement Agreement Dear Holder: HEPION PHARMACEUTICALS, INC. (the “Company”) is pleased to offer (this “Offer”) to you (“Holder”, “you” or similar terminology) t |
|
| February 16, 2024 |
Exhibit 10.2 AMENDMENT NO. 1 TO SERIES A COMMON STOCK PURCHASE WARRANT This AMENDMENT NO. 1 TO SERIES A COMMON STOCK PURCHASE WARRANT (this “Amendment”) is entered into as of February [ ], 2024, by and between Hepion Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and (the “Holder”). WHEREAS, the Holder is the holder of a Series A Common Stock Purchase Warrant, issued as of October |
|
| February 16, 2024 |
590 Madison Avenue, 36th Floor, New York, NY 10022, 212-624-2060 Member FINRA, SIPC Exhibit 99.1 CONFIDENTIAL February 15, 2024 Hepion Pharmaceuticals, Inc. Attention: John Cavan 399 Thornall Street, First Floor Edison, NJ 08837 The purpose of this financial advisory agreement (this “Agreement”) is to confirm the engagement of A.G.P./Alliance Global Partners (“A.G.P.”) by Hepion Pharmaceuticals, Inc. (the “Company”) to render Financial Services (as defined below) to the Company. |
|
| February 16, 2024 |
Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| February 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 15, 2024 Hepion Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36856 46-2783806 (State or other jurisdiction of incorporation) (Com |
|
| February 16, 2024 |
Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| February 14, 2024 |
US4268973025 / HEPION PHARMACEUTICALS INC / ARMISTICE CAPITAL, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 7, 2024 Hepion Pharmaceuticals, Inc. |
|
| January 3, 2024 |
Letter from BDO USA, P.C. to the Securities and Exchange Commission dated January 2, 2024. Exhibit 16.1 Tel: 301-354-2500 Fax: 301-354-2501 www.bdo.com 12505 Park Potomac Ave, Suite 700 Potomac, MD 20854 January 2, 2024 Securities and Exchange Commission 100 F Street N.E. Washington, D.C. 20549 We have been furnished with a copy of the response to Item 4.01 of Form 8-K for the event that occurred on December 27, 2023, to be filed by our former client, Hepion Pharmaceuticals, Inc. We agr |
|
| January 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 27, 2023 Hepion Pharmaceuticals, Inc. |
|
| December 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 4, 2023 Hepion Pharmaceuticals, Inc. |
|
| December 7, 2023 |
Exhibit 99.1 Hepion Pharmaceuticals Announces Restructuring Plan to Enhance Shareholder Value and Management Changes Restructuring program purpose is to preserve capital and optimize clinical development program Management plans to continue to evaluate its Phase 2b ASCEND-NASH clinical trial taking in account current market environment Cash runway extended into Q2 2025 EDISON, N.J., December 7, 20 |
|
| November 20, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2023 Or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36856 |
|
| November 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 Commission File Number: 001-36856 NOTIFICATION OF LATE FILING ¨ Form 10-K ¨ Form 20-F ¨ Form 11-K x Form 10-Q ¨ Form 10-D ¨ Form N-SAR ¨ Form N-CSR For Period Ended: September 30, 2023 ¨ Transition Report on Form 10-K ¨ Transition Report on Form 10-Q ¨ Transition Report on Form 20-F ¨ Transition Report on Form N-SA |
|
| November 6, 2023 |
Hepion Pharmaceuticals, Inc. 399 Thornall Street, First Floor Edison, NJ 08837 Hepion Pharmaceuticals, Inc. 399 Thornall Street, First Floor Edison, NJ 08837 November 6, 2023 VIA EDGAR United States Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attention: Tim Buchmiller Re: Hepion Pharmaceuticals, Inc. Form S-1 Registration Statement Filed October 31, 2023 File No. 333-275231 Ladies and Gentlemen: Pursuant to Rule 461 of the General Rules and R |
|
| October 31, 2023 |
Exhibit 107 Calculation of Filing Fee Tables FORM S-1 (Form Type) HEPION PHARMACEUTICALS, INC. |
|
| October 31, 2023 |
As filed with the Securities and Exchange Commission on October 31, 2023 As filed with the Securities and Exchange Commission on October 31, 2023 Registration Statement No. |
|
| October 3, 2023 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of September 29, 2023, between Hepion Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”). WHEREAS, subject to the terms and condit |
|
| October 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 28, 2023 HEPION PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36856 46-2783806 (State or other jurisdiction of incorporat |
|
| October 3, 2023 |
Exhibit 4.3 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| October 3, 2023 |
Exhibit 99.1 Hepion Pharmaceuticals Announces $5.0 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market under Nasdaq Rules EDISON, N.J., September 29, 2023 - Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on artificial intelligence assisted therapeutic drug development for the treatment of non-alcoholic steatohepat |
|
| October 3, 2023 |
Exhibit 4.1 PRE-FUNDED COMMON STOCK PURCHASE WARRANT HEPION PHARMACEUTICALS, INC. Warrant Shares: 580,393 Initial Exercise Date: October 3, 2023 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on |
|
| October 3, 2023 |
Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| October 2, 2023 |
Filed Pursuant to Rule 424(b)(5) Registration No. 333-254996 PROSPECTUS SUPPLEMENT (To Prospectus dated November 24, 2021) 400,000 Shares of Common Stock 580,393 Pre-Funded Warrants to Purchase 580,393 Shares of Common Stock We are offering 400,000 shares of common stock to an institutional investor at an offering price of $5.10 per share. In addition, we are also offering pre-funded warrants to p |
|
| September 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 30, 2023 Hepion Pharmaceuticals, Inc. |
|
| August 14, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2023 Or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36856 HEPI |
|
| July 24, 2023 |
Exhibit 99.1 1 1 Rencofilstat (CRV431): A Novel Drug Candidate for NASH, Fibrosis, and HCC July 2023 Creating a Therapeutic Ecosystem NASDAQ: HEPA 2 This presentation may contain forward - looking statements within the meaning of Section 27 A of the Securities Act of 1933 and Section 21 E of the Securities Exchange Act of 1934 . Such forward - looking statements are characterized by future or cond |
|
| July 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 24, 2023 Hepion Pharmaceuticals, Inc. |
|
| July 21, 2023 |
Up to $24,000,000 Common Stock Hepion Pharmaceuticals, Inc. Filed Pursuant to Rule 424(b)(5) Registration No. 333-254996 PROSPECTUS SUPPLEMENT (To Prospectus dated November 24, 2021) Up to $24,000,000 Common Stock Hepion Pharmaceuticals, Inc. We have entered into a Controlled Equity OfferingSM Sales Agreement (the “Sales Agreement”) with Cantor Fitzgerald & Co. (“Cantor Fitzgerald”), relating to shares of our common stock, $0.001 par value per share, offer |
|
| July 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 21, 2023 HEPION PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36856 46-2783806 (State or other jurisdiction of incorporation ) |
|
| July 21, 2023 |
Exhibit 1.1 Hepion Pharmaceuticals, Inc. Shares of Common Stock (par value $ 0.0001 per share) Controlled Equity OfferingSM Sales Agreement July 21, 2023 Cantor Fitzgerald & Co. 499 Park Avenue New York, NY 10022 Ladies and Gentlemen: Hepion Pharmaceuticals, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Cantor Fitzgerald & Co. (the “Agent”), as follow |
|
| July 14, 2023 |
As filed with the Securities and Exchange Commission on July 14, 2023 As filed with the Securities and Exchange Commission on July 14, 2023 Registration No. |
|
| July 14, 2023 |
Exhibit 107 Calculation of Filing Fee Tables FORM S-8 (Form Type) HEPION PHARMACEUTICALS, INC. |
|
| June 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 22, 2023 Hepion Pharmaceuticals, Inc. |
|
| May 22, 2023 |
Exhibit 99.1 1 1 Rencofilstat (CRV431): A Novel Drug Candidate for NASH, Fibrosis, and HCC May 2023 Creating a Therapeutic Ecosystem NASDAQ:HEPA 2 This presentation may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such forward-looking statements are characterized by future or conditional v |
|
| May 22, 2023 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 22, 2023 Hepion Pharmaceuticals, Inc. |
|
| May 22, 2023 |
Exhibit 99.2 Hepion Pharmaceuticals’ Phase 2 ‘ALTITUDE-NASH’ Trial Achieves Primary and Secondary Endpoints, Including Improvement in Liver Function and Multiple NASH Biomarkers - Improvements in physiologic liver function and key NASH biomarkers including ALT, ProC3, PIIINP and ELF - - Results reinforce rencofilstat’s direct antifibrotic mode of action; increases confidence for reductions in fibr |
|
| May 12, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2023 Or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36856 HEP |
|
| May 10, 2023 |
Hepion Pharmaceuticals, Inc. Announces Reverse Stock Split Exhibit 99.1 Hepion Pharmaceuticals, Inc. Announces Reverse Stock Split EDISON, NJ, / May 10, 2023 / Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of fibrotic diseases, including non-alcoholic steatohepatitis (“NASH”), hepatocellular carcinoma (“HCC”), and other |
|
| May 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): May 10, 2023 HEPION PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36856 46-2783806 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| May 10, 2023 |
Exhibit 3.1 CERTIFICATE OF AMENDMENT to the CERTIFICATE OF INCORPORATION of HEPION PHARMACEUTICALS, INC. HEPION PHARMACEUTICALS, INC., a corporation organized and existing under the General Corporation Law of the State of Delaware (the “Corporation”), does hereby certify as follows: FIRST: The name of the Corporation is Hepion Pharmaceuticals, Inc. The Certificate of Incorporation was filed with t |
|
| April 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Defin |
|
| April 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Defin |
|
| April 10, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the year ended December 31, 2022 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 001-36856 HEPION PHARMA |
|
| April 10, 2023 |
Exhibit 21.1 LIST OF SUBSIDIARIES Name State or Other Jurisdiction of Incorporation ContraVir Research, Inc. Delaware Hepion Research Corp. Canada |
|
| April 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 Commission File Number: 001-36856 NOTIFICATION OF LATE FILING x Form 10-K ¨ Form 20-F ¨ Form 11-K ¨ Form 10-Q ¨ Form 10-D ¨ Form N-SAR ¨ Form N-CSR For Period Ended: December 31, 2022 ¨ Transition Report on Form 10-K ¨ Transition Report on Form 10-Q ¨ Transition Report on Form 20-F ¨ Transition Report on Form N-SAR |
|
| December 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): December 15, 2022 HEPION PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36856 46-2783806 (State or Other Jurisdiction of Incorporation) (Com |
|
| November 21, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Defin |
|
| November 14, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2022 Or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36856 |
|
| November 9, 2022 |
Exhibit 3.3 CERTIFICATE OF AMENDMENT OF CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS, WHICH HAVE NOT BEEN SET FORTH IN THE CERTIFICATE OF INCORPORATION OR IN ANY AMENDMENT THERETO, OF THE SERIES F CONVERTIBLE REDEEMABLE PREFERRED STOCK OF HEPION PHARMACEUTICALS, INC. Pursuant to Section 151 of the General Corporation Law of the State of Delaware I, Robert Foster, do hereby cer |
|
| November 9, 2022 |
Exhibit 3.1 HEPION PHARMACEUTICALS, INC. CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES F CONVERTIBLE REDEEMABLE PREFERRED STOCK PURSUANT TO SECTION 151 OF THE delaware GENERAL CORPORATION LAW The undersigned, Robert Foster, does hereby certify that: 1. He is the Chief Executive Officer of Hepion Pharmaceuticals, Inc., a Delaware corporation (the “Corporation”). 2. The |
|
| November 9, 2022 |
Exhibit 3.4 CERTIFICATE OF AMENDMENT OF CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS, WHICH HAVE NOT BEEN SET FORTH IN THE CERTIFICATE OF INCORPORATION OR IN ANY AMENDMENT THERETO, OF THE SERIES G CONVERTIBLE REDEEMABLE PREFERRED STOCK OF HEPION PHARMACEUTICALS, INC. Pursuant to Section 151 of the General Corporation Law of the State of Delaware I, Robert Foster, do hereby cer |
|
| November 9, 2022 |
Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is made and entered into as of November , 2022, between Hepion Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and each of the several purchasers signatory hereto (each such purchaser, a “Purchaser” and, collectively, the “Purchasers”). This Agreement is made pursuant to the Secu |
|
| November 9, 2022 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of November , 2022, between Hepion Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). Recitals A. The Company and |
|
| November 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: x Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Defin |
|
| November 9, 2022 |
Form of Side Letter between Hepion Pharmaceuticals, Inc. and each investor, dated November 4, 2022 Exhibit 10.3 Hepion Pharmaceuticals, Inc. 399 Thornall Street, First Floor Edison, NJ 08837 November , 2022 [INVESTOR NAME] [ADDRESS] [ADDRESS] Attn: ]] Email: [] Re: Securities Purchase Agreement, dated as of November , 2022 (the “Securities Purchase Agreement”), by and among Hepion Pharmaceuticals, Inc., a Delaware corporation (the “Company”), the undersigned purchaser (the “Purchaser” |
|
| November 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): November 4, 2022 HEPION PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36856 46-2783806 (State or Other Jurisdiction of Incorporation) (Comm |
|
| November 9, 2022 |
Exhibit 3.2 HEPION PHARMACEUTICALS, INC. CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES G CONVERTIBLE REDEEMABLE PREFERRED STOCK PURSUANT TO SECTION 151 OF THE delaware GENERAL CORPORATION LAW The undersigned, Robert Foster, does hereby certify that: 1. He is the Chief Executive Officer of Hepion Pharmaceuticals, Inc., a Delaware corporation (the “Corporation”). 2. The |
|
| November 9, 2022 |
Exhibit 99.1 Hepion Pharmaceuticals Announces Pricing of $20.0 Million Private Placement of Convertible Redeemable Preferred Stock November 4, 2022 EDISON, N.J., Nov. 04, 2022 — Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of fibrotic diseases, including non-alc |
|
| October 17, 2022 |
Exhibit 99.1 1 1 Rencofilstat (CRV431): A Novel Drug Candidate for NASH, Fibrosis, and HCC October 2022 Creating a Therapeutic Ecosystem NASDAQ: HEPA 2 This presentation may contain forward - looking statements within the meaning of Section 27 A of the Securities Act of 1933 and Section 21 E of the Securities Exchange Act of 1934 . Such forward - looking statements are characterized by future or c |
|
| October 17, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 17, 2022 Hepion Pharmaceuticals, Inc. |
|
| August 15, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2022 Or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36856 HEPI |
|
| August 5, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2022 Hepion Pharmaceuticals, Inc. |
|
| July 26, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| July 25, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| June 30, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| June 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 27, 2022 Hepion Pharmaceuticals, Inc. |
|
| June 28, 2022 |
Exhibit 99.1 Hepion Pharmaceuticals Further Strengthens Board with Appointments of Accomplished Biopharmaceutical Executives, Mr. Anand Reddi and Dr. Kaouthar Lbiati EDISON, N.J., June 28, 2022 - Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical mid-stage biopharmaceutical company focused on Artificial Intelligence (?AI?)-driven therapeutic drug development for the treatment of non-alcoholic |
|
| June 27, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 24, 2022 Hepion Pharmaceuticals, Inc. |
|
| June 24, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| June 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| June 6, 2022 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 3, 2022 Hepion Pharmaceuticals, Inc. |
|
| May 31, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| May 27, 2022 |
Exhibit 99.1 1 1 Rencofilstat (CRV431): A liver-targeting drug candidate for NASH and HCC Todd M. Hobbs MD ? CMO May 27, 2022 smart drug smart technology smart development 2 Complex and Associated Diseases The Challenges New approaches to developing NASH and HCC therapeutics are needed NASH ? No FDA drugs approved ? Traditional metabolism-regulating drugs largely not efficacious ? Multifactorial d |
|
| May 27, 2022 |
Exhibit 99.2 Hepion Pharmaceuticals Highlights Upcoming Phase 2 Clinical Trials of Recofilstat at 5th Global NASH Congress EDISON, N.J., May 27, 2022 - Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (?AI?)-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (?NASH?) and hepatocellular carc |
|
| May 27, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 27, 2022 Hepion Pharmaceuticals, Inc. |
|
| May 16, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2022 Or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36856 HEP |
|
| April 29, 2022 |
DEF 14A 1 tm223712d2def14a.htm DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as |
|
| April 20, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a party other than the Registrant ? Check the appropriate box: x Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| April 8, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the year ended December 31, 2021 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 001-36856 HEPION PHARMA |
|
| April 8, 2022 |
EX-21.1 2 hepa-2021123110kxex211.htm EX-21.1 Exhibit 21.1 LIST OF SUBSIDIARIES Name State or Other Jurisdiction of Incorporation ContraVir Research, Inc. Delaware Hepion Research Corp. Canada |
|
| March 31, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 Commission File Number: 001-36856 NOTIFICATION OF LATE FILING x Form 10-K ? Form 20-F ? Form 11-K ? Form 10-Q ? Form 10-D ? Form N-SAR ? Form N-CSR For Period Ended: December 31, 2021 ? Transition Report on Form 10-K ? Transition Report on Form 10-Q ? Transition Report on Form 20-F ? Transition Report on Form N-SAR |
|
| February 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1 )* Hepion Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 426897104 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to desi |
|
| February 10, 2022 |
HEPA / Hepion Pharmaceuticals Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 1)* Name of issuer: Hepion Pharmaceuticals Inc. Title of Class of Securities: Common Stock CUSIP Number: 426897104 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule is |
|
| January 19, 2022 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Hepion Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.0001 (Title of Class of Securities) 426897104 (CUSIP Number) December 31, 2021 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pursuant to |
|
| January 12, 2022 |
Hepion Pharmaceuticals Announces Death of Director, Thomas Adams Exhibit 99.1 Hepion Pharmaceuticals Announces Death of Director, Thomas Adams EDISON, N.J., January 13, 2022 ? It is with profound sadness that Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) announces the passing of Thomas Adams, Ph.D., a member of its Board of Directors. Dr. Adams died of natural causes on January 9, 2022. A seasoned biotechnology veteran, Dr. Adams was appointed to Hepion?s Board in |
|
| January 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 9, 2022 Hepion Pharmaceuticals, Inc. |
|
| January 10, 2022 |
EX-99.1 2 tm222379d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 1 1 Rencofilstat (CRV431): A liver - targeting drug candidate for NASH and HCC January 2022 | INVESTOR PRESENTATION smart drug smart technology smart development 2 This presentation may contain forward - looking statements within the meaning of Section 27 A of the Securities Act of 1933 and Section 21 E of the Securities Exchange Act of 1934 |
|
| January 10, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 10, 2022 Hepion Pharmaceuticals, Inc. |
|
| January 6, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 6, 2022 Hepion Pharmaceuticals, Inc. |
|
| January 6, 2022 |
Hepion Pharmaceuticals Announces USAN Selection of “Rencofilstat” as Nonproprietary Name for CRV431 Exhibit 99.1 Hepion Pharmaceuticals Announces USAN Selection of ?Rencofilstat? as Nonproprietary Name for CRV431 EDISON, N.J., January 6, 2022 - Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (?AI?)-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (?NASH?) and other liver diseases, toda |
|
| December 21, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 21, 2021 Hepion Pharmaceuticals, Inc. |
|
| December 21, 2021 |
Exhibit 99.1 Hepion Pharmaceuticals Announces FDA Clearance of IND Application for CRV431 in the Treatment of Liver Cancer - New IND Expands Liver Disease Pipeline for CRV431 - - IND Clearance Allows CRV431 to Move Directly into Phase 2 for Hepatocellular Carcinoma Treatment - - New IND Provides for Complementary Therapeutic Approach of Treating NASH and Liver Cancer with a Single Once-a-Day Oral |
|
| November 30, 2021 |
Hepion Pharmaceuticals Receives FDA Fast Track Designation for CRV431 for the Treatment of NASH Exhibit 99.1 Hepion Pharmaceuticals Receives FDA Fast Track Designation for CRV431 for the Treatment of NASH EDISON, N.J., November 30, 2021 - Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (?AI?)-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (?NASH?) and other liver diseases, today |
|
| November 30, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 30, 2021 Hepion Pharmaceuticals, Inc. |
|
| November 22, 2021 |
Hepion Pharmaceuticals, Inc. 399 Thornall Street, First Floor Edison, NJ 08837 CORRESP 1 filename1.htm Hepion Pharmaceuticals, Inc. 399 Thornall Street, First Floor Edison, NJ 08837 November 22, 2021 VIA EDGAR United States Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attention: Tim Buchmiller Re: Hepion Pharmaceuticals, Inc. Amendment No. 1 to Form S-3 Registration Statement Filed November 19, 2021 File No. 333-254996 Ladies and Gentlemen: Pu |
|
| November 19, 2021 |
As filed with the Securities and Exchange Commission on November 19, 2021 As filed with the Securities and Exchange Commission on November 19, 2021 Registration No. |
|
| November 16, 2021 |
Exhibit 99.1 Hepion Pharmaceuticals and FibroFind Announce Anti-Cancer Activity of CRV431 in a Nonclinical Liver Cancer Study EDISON, N.J., November 16, 2021 - Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (?AI?)-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (?NASH?) and other liver |
|
| November 16, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 16, 2021 Hepion Pharmaceuticals, Inc. |
|
| November 15, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2021 Or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Numbe |
|
| November 10, 2021 |
Hepion Pharmaceuticals Announces Poster Details for the Upcoming AASLD The Liver Meeting® 2021 Exhibit 99.1 Hepion Pharmaceuticals Announces Poster Details for the Upcoming AASLD The Liver Meeting? 2021 EDISON, N.J., November 10, 2021 - Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (?AI?)-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (?NASH?) and other liver diseases, today a |
|
| November 10, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2021 Hepion Pharmaceuticals, Inc. |
|
| November 10, 2021 |
Exhibit 99.2 Anti-Cancer Mechanism of Hepion Pharmaceuticals? CRV431 Highlighted in Scripps Research Institute Poster at AASLD, The Liver Meeting? 2021 EDISON, N.J., November 10, 2021 - Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (?AI?)-driven therapeutic drug development for the treatment of non-alcoholic steatohepatiti |
|
| October 8, 2021 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 8, 2021 Hepion Pharmaceuticals, Inc. |
|
| October 7, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 7, 2021 Hepion Pharmaceuticals, Inc. |
|
| October 7, 2021 |
Hepion Pharmaceuticals to Participate in the H.C. Wainwright 5th Annual NASH Investor Conference Exhibit 99.1 Hepion Pharmaceuticals to Participate in the H.C. Wainwright 5th Annual NASH Investor Conference EDISON, N.J., October 7, 2021 - Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (?AI?)-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (?NASH?) and liver disease, today announce |
|
| September 30, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 30, 2021 Hepion Pharmaceuticals, Inc. |
|
| September 30, 2021 |
Exhibit 99.1 A BETTER APPROACH TO DRUG DEVELOPMENT FOR LIVER DISEASES October 202 1 | INVESTOR PRESENTATION smart drug smart technology smart development 2 This presentation may contain forward - looking statements within the meaning of Section 27 A of the Securities Act of 1933 and Section 21 E of the Securities Exchange Act of 1934 . Such forward - looking statements are characterized by future |
|
| September 29, 2021 |
All Endpoints Met in Hepion Pharmaceuticals’ Drug-Drug Interaction Study with CRV431 Exhibit 99.1 All Endpoints Met in Hepion Pharmaceuticals? Drug-Drug Interaction Study with CRV431 EDISON, N.J., September 29, 2021 - Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (?AI?)-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (?NASH?) and liver disease, today announced results |
|
| September 29, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 29, 2021 Hepion Pharmaceuticals, Inc. |
|
| September 13, 2021 |
INVESTOR UPDATE September 13 , 2021 Nasdaq: HEPA Exhibit 99.2 INVESTOR UPDATE September 13 , 2021 Nasdaq: HEPA 2 This presentation may contain forward - looking statements within the meaning of Section 27 A of the Securities Act of 1933 and Section 21 E of the Securities Exchange Act of 1934 . Such forward - looking statements are characterized by future or conditional verbs such as ?may,? ?will,? ?expect,? ?intend,? ?anticipate,? believe,? ?est |
|
| September 13, 2021 |
Exhibit 99.1 Additional Data from Hepion Pharmaceuticals? Phase 2a ?AMBITION? Trial Further Strengthens CRV431 Clinical Profile and Paves Way for Initiation of Phase 2b ?ASCEND-NASH? Clinical Program ? Pro-C3 and ALT reductions point to anti-inflammatory and antifibrotic effects of CRV431 ? PK-PD models successfully predict early reductions in Pro-C3 and ALT ? Hepion?s proprietary AI-POWR? and mac |
|
| September 13, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 13, 2021 Hepion Pharmaceuticals, Inc. |
|
| September 7, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Defin |
|
| August 23, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 20, 2021 Hepion Pharmaceuticals, Inc. |
|
| August 23, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: x Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Defin |
|
| August 23, 2021 |
Exhibit 3.1 AMENDMENT TO THE BYLAWS OF HEPION PHARMACEUTICALS, INC. (the ?Corporation?) Section 5 of Article I of the Bylaws of the Corporation (the ?Bylaws?), is hereby amended and restated in its entirety as follows: ?5. Quorum; Adjournments; Postponement. The holders of stock representing one-third (33.33%) of the voting power of all shares of stock issued and outstanding and entitled to vote, |
|
| August 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2021 Or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001 |
|
| July 26, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 23, 2021 Hepion Pharmaceuticals, Inc. |
|
| July 26, 2021 |
Exhibit 99.1 Hepion Pharmaceuticals Announces Postponement of 2021 Annual Meeting of Stockholders EDISON, N.J., July 23, 2021 (GLOBE NEWSWIRE) - Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver disease arising from non-alcoholic steatohepatitis ("NASH"), today announced the postponement |
|
| July 13, 2021 |
Exhibit 99.1 Hepion Pharmaceuticals Announces Positive Topline Data from Phase 2a ?AMBITION? NASH Trial; All Primary Endpoints Achieved ? Safety, Tolerability and Pharmacokinetics (?PK?) Primary Endpoints Met ? Reductions in Liver Transaminases Indicate Dose-Related Improvements in Key NASH Biomarker ? Concentration-Effect Relationship Demonstrated for ALT Reductions ? Multiomic Analyses and Machi |
|
| July 13, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 13, 2021 Hepion Pharmaceuticals, Inc. |
|
| June 25, 2021 |
Hepion Pharmaceuticals Announces Adjournment of Annual Meeting Exhibit 99.1 Hepion Pharmaceuticals Announces Adjournment of Annual Meeting EDISON, N.J., June 25, 2021 - Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver disease arising from non-alcoholic steatohepatitis ("NASH"), today announced that its 2021 Annual Meeting of Stockholders, scheduled |
|
| June 25, 2021 |
Hepion Pharmaceuticals, Inc. Press Release dated June 25, 2021 Exhibit 99.1 Hepion Pharmaceuticals Announces Adjournment of Annual Meeting EDISON, N.J., June 25, 2021 - Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver disease arising from non-alcoholic steatohepatitis ("NASH"), today announced that its 2021 Annual Meeting of Stockholders, scheduled |
|
| June 25, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 25, 2021 Hepion Pharmaceuticals, Inc. |
|
| June 25, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 25, 2021 Hepion Pharmaceuticals, Inc. |
|
| June 9, 2021 |
Hepion Pharmaceuticals to be Added to the Russell Microcap® Index EX-99.1 2 tm2119207d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Hepion Pharmaceuticals to be Added to the Russell Microcap® Index EDISON, N.J., June 9, 2021 - Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA, “Hepion”), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“NASH”) and liver di |
|
| June 9, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 9, 2021 Hepion Pharmaceuticals, Inc. |
|
| May 14, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2021 Or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 00 |
|
| May 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Defin |
|
| May 6, 2021 |
Exhibit 99.1 Hepion Pharmaceuticals Completes Final Patient Recruitment in Phase 2a 'AMBITION' Clinical Trial of CRV431 for the Treatment of Advanced NASH EDISON, N.J., May 6, 2021 - Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver disease arising from non-alcoholic steatohepatitis ("NA |
|
| May 6, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2021 Hepion Pharmaceuticals, Inc. |
|
| April 29, 2021 |
Exhibit 99.1 Hepion Pharmaceuticals Presents Machine Learning ?Learn and Confirm? Modeling Strategy at 4th Global NASH Congress EDISON, N.J., April 29, 2021 - Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA, ?Hepion?), a clinical stage biopharmaceutical company focused on Artificial Intelligence (?AI?) - driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (?NASH?) and |
|
| April 29, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 29, 2021 Hepion Pharmaceuticals, Inc. |
|
| April 28, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ? Check the appropriate box: x Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| April 28, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the year ended December 31, 2020 Or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36856 HEPION PHARMACEUTICA |
|
| April 2, 2021 |
As filed with the Securities and Exchange Commission on April 2, 2021 Registration No. |
|
| April 2, 2021 |
Form of Subordinated Indenture Exhibit 4.2 HEPION PHARMACEUTICALS, INC., ISSUER AND [TRUSTEE], TRUSTEE INDENTURE DATED AS OF , 20 SUBORDINATED DEBT SECURITIES -1- TABLE OF CONTENTS Page ARTICLE 1 DEFINITIONS 5 Section 1.01 Definitions of Terms 5 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 8 Section 2.01 Designation and Terms of Securities 8 Section 2.02 Form of Securities and Trustee' |
|
| April 2, 2021 |
Exhibit 4.1 HEPION PHARMACEUTICALS, INC., ISSUER AND [TRUSTEE], TRUSTEE INDENTURE DATED AS OF , 20 SENIOR DEBT SECURITIES -1- TABLE OF CONTENTS Page ARTICLE I DEFINITIONS 5 Section 1.1 Definitions of Terms 5 ARTICLE II ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 8 Section 2.1 Designation and Terms of Securities 8 Section 2.2 Form of Securities and Trustee's Certif |
|
| March 31, 2021 |
? ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ? ? (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the year ended December 31, 2020 Or ? ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to ? Commission File Number 001-36856 ? HEPION |
|
| March 31, 2021 |
? Exhibit 21.1 ? LIST OF SUBSIDIARIES ? Name ? State or Other Jurisdiction of Incorporation ContraVir Research Inc. ? Delaware Hepion Research Corp ? Canada ? |
|
| March 23, 2021 |
Exhibit 99.1 DIAMOND Mouse Model is Latest in a String of Nonclinical Studies Confirming the Antifibrotic Effects of Hepion Pharmaceutical’s Lead Drug, CRV431 EDISON, N.J., March 23, 2021 - Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA, “Hepion”), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”) - driven therapeutic drug development for the treatment of non-alcoholi |
|
| March 23, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 23, 2021 Hepion Pharmaceuticals, Inc. |
|
| March 11, 2021 |
Hepion Pharmaceuticals to Present on CRV431 and AI-POWR™ at NASH-TAG 2021 Exhibit 99.1 Hepion Pharmaceuticals to Present on CRV431 and AI-POWR™ at NASH-TAG 2021 EDISON, N.J., March 11, 2021 - Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA, “Hepion”), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“NASH”) and liver disease, today announced that it will |
|
| March 11, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 11, 2021 Hepion Pharmaceuticals, Inc. |
|
| February 24, 2021 |
Hepion Pharmaceuticals, Inc. SC 13G EXHIBIT 1 JOINT ACQUISITION STATEMENT PURSUANT TO SECTION 240.13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional |
|
| February 24, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Hepion Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 426897104 (CUSIP Number) February 16, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designat |
|
| February 18, 2021 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Hepion Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.0001 (Title of Class of Securities) 426897104 (CUSIP Number) February 16, 2021 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pursuant to w |
|
| February 17, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 12, 2021 Hepion Pharmaceuticals, Inc. |
|
| February 17, 2021 |
Form of Representative’s Warrant (incorporated by reference to Annex A of Exhibit 1.1 hereto) EX-1.1 2 tm216528d4ex1-1.htm EXHIBIT 1.1 Exhibit 1.1 Execution Copy UNDERWRITING AGREEMENT between HEPION PHARMACEUTICALS INC. and THINKEQUITY, A DIVISION OF FORDHAM FINANCIAL MANAGEMENT, INC., as Representative of the Several Underwriters HEPION PHARMACEUTICALS INC. UNDERWRITING AGREEMENT New York, New York February 16, 2021 ThinkEquity A Division of Fordham Financial Management, Inc. As Represen |
|
| February 17, 2021 |
Hepion Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock EX-99.1 4 tm216528d4ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Hepion Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock Edison, NJ – February 12, 2021 – Hepion Pharmaceuticals, Inc. (NASDAQ: HEPA) (“Hepion Pharmaceuticals” or the “Company”) today announced that it intends to offer to sell shares of its common stock in an underwritten public offering. All of the shares of common st |
|
| February 17, 2021 |
Hepion Pharmaceuticals Announces Pricing of Public Offering Exhibit 99.2 Hepion Pharmaceuticals Announces Pricing of Public Offering EDISON, N.J., February 16, 2021 - Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver disease arising from non-alcoholic steatohepatitis ("NASH"), today announced the pricing of its underwritten public offering of 44, |
|
| February 16, 2021 |
CUSIP No: 426897104 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2. (Amendment No. 2)* Hepion Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 426897104 (CUSI |
|
| February 16, 2021 |
Subject To Completion, Dated February 16, 2021 424B5 1 tm216528d1424b5.htm 424B5 Filed Pursuant to Rule 424(b)(5) Registration No. 333-229534 The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to these securities has been declared effective by the Securities and Exchange Commission. This preliminary prospectus supplement and the accompanying prospectus are not an offe |
|
| February 16, 2021 |
Filed Pursuant to Rule 424(b)(5) Registration No. 333-229534 PROSPECTUS SUPPLEMENT (To Prospectus dated February 19, 2019) 44,200,000 Shares Common Stock Hepion Pharmaceuticals, Inc. We are offering 44,200,000 shares of our common stock. The purchase price for each share is $2.00. Our common stock trades on The Nasdaq Capital Market under the symbol “HEPA.” On February 12, 2021, the last reported |
|
| February 12, 2021 |
A BETTER APPROACH TO DRUG DEVELOPMENT FOR LIVER DISEASES February 202 1 | INVESTOR PRESENTATION smart drug smart technology smart development Filed pursuant to Rule 433 of the Securities Act of 1933 Issuer Free Writing Prospectus dated February 12 , 2021 2 This presentation may contain forward - looking statements within the meaning of Section 27 A of the Securities Act of 1933 and Section 21 E of the Securities Exchange Act of 1934 . |
